Iams Wealth Management LLC Grows Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Iams Wealth Management LLC increased its holdings in AstraZeneca PLC (NASDAQ:AZN) by 72.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,080 shares of the company’s stock after buying an additional 11,369 shares during the period. Iams Wealth Management LLC’s holdings in AstraZeneca were worth $1,774,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bank of Montreal Can lifted its holdings in AstraZeneca by 109.6% in the 3rd quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock valued at $238,397,000 after purchasing an additional 1,605,758 shares in the last quarter. Franklin Resources Inc. increased its position in AstraZeneca by 8.7% during the 3rd quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock worth $1,492,649,000 after purchasing an additional 1,522,715 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in AstraZeneca during the 3rd quarter worth approximately $72,437,000. Fisher Asset Management LLC grew its position in AstraZeneca by 5.3% in the third quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock valued at $816,509,000 after acquiring an additional 524,175 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its position in AstraZeneca by 63.5% in the third quarter. Assenagon Asset Management S.A. now owns 871,893 shares of the company’s stock valued at $67,929,000 after acquiring an additional 338,566 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AZN has been the subject of several recent research reports. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Stock Performance

AZN stock opened at $70.06 on Wednesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The stock has a market capitalization of $217.27 billion, a price-to-earnings ratio of 33.58, a PEG ratio of 1.13 and a beta of 0.46. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68. The stock’s fifty day moving average is $66.69 and its two-hundred day moving average is $74.02.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period last year, the business posted $0.87 earnings per share. On average, research analysts predict that AstraZeneca PLC will post 4.12 EPS for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.